271 related articles for article (PubMed ID: 17070436)
1. The role of lipoprotein-associated phospholipase A(2) in the metabolic syndrome and diabetes.
Noto H; Chitkara P; Raskin P
J Diabetes Complications; 2006; 20(6):343-8. PubMed ID: 17070436
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular events with increased lipoprotein-associated phospholipase A(2) and low high-density lipoprotein-cholesterol: the Veterans Affairs HDL Intervention Trial.
Robins SJ; Collins D; Nelson JJ; Bloomfield HE; Asztalos BF
Arterioscler Thromb Vasc Biol; 2008 Jun; 28(6):1172-8. PubMed ID: 18356553
[TBL] [Abstract][Full Text] [Related]
3. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
[TBL] [Abstract][Full Text] [Related]
4. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
6. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
7. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS
Prev Cardiol; 2010; 13(3):130-4. PubMed ID: 20626668
[TBL] [Abstract][Full Text] [Related]
9. High-sensitivity C-reactive protein and the hypertriglyceridemic waist in patients with type 2 diabetes and metabolic syndrome.
Rosolova H; Petrlova B; Simon J; Sifalda P; Sipova I
Med Sci Monit; 2008 Aug; 14(8):CR411-5. PubMed ID: 18667998
[TBL] [Abstract][Full Text] [Related]
10. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
[TBL] [Abstract][Full Text] [Related]
11. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
[TBL] [Abstract][Full Text] [Related]
12. Non-conventional markers of atherosclerosis before and after gastric banding surgery.
Hanusch-Enserer U; Zorn G; Wojta J; Kopp CW; Prager R; Koenig W; Schillinger M; Roden M; Huber K
Eur Heart J; 2009 Jun; 30(12):1516-24. PubMed ID: 19380349
[TBL] [Abstract][Full Text] [Related]
13. Effects of V279F in the Lp-PLA(2) gene on markers of oxidative stress and inflammation in Koreans.
Paik JK; Chae JS; Jang Y; Kim JY; Kim OY; Jeong TS; Lee SH; Lee JH
Clin Chim Acta; 2010 Apr; 411(7-8):486-93. PubMed ID: 20080080
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
Oldgren J; James SK; Siegbahn A; Wallentin L
Eur Heart J; 2007 Mar; 28(6):699-704. PubMed ID: 17314110
[TBL] [Abstract][Full Text] [Related]
15. Waist circumference adds to the variance in plasma C-reactive protein levels in elderly patients with metabolic syndrome.
Dupuy AM; Jaussent I; Lacroux A; Durant R; Cristol JP; Delcourt C
Gerontology; 2007; 53(6):329-39. PubMed ID: 17551260
[TBL] [Abstract][Full Text] [Related]
16. [Lipoprotein (a) and ischemic heart diseases in patients with type 2 diabetes].
Ben Hamda K; Masmoudi AS; Mandhouj O; Hammami S; Attia N; Smaoui M; Zidi MA; Nabli N; Chaaba R; Mahjoub S; Ben Farhat M; Hammami M
Arch Inst Pasteur Tunis; 2002; 79(1-4):27-33. PubMed ID: 15072242
[TBL] [Abstract][Full Text] [Related]
17. Alterations in biomarkers of cardiovascular disease (CVD) in active acromegaly.
Boero L; Manavela M; Gómez Rosso L; Insua C; Berardi V; Fornari MC; Brites F
Clin Endocrinol (Oxf); 2009 Jan; 70(1):88-95. PubMed ID: 19128365
[TBL] [Abstract][Full Text] [Related]
18. Plasma cholesteryl ester transfer, but not cholesterol esterification, is related to lipoprotein-associated phospholipase A2: possible contribution to an atherogenic lipoprotein profile.
Dullaart RP; Constantinides A; Perton FG; van Leeuwen JJ; van Pelt JL; de Vries R; van Tol A
J Clin Endocrinol Metab; 2011 Apr; 96(4):1077-84. PubMed ID: 21252249
[TBL] [Abstract][Full Text] [Related]
19. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
20. Association of Lp-PLA(2) activity and LDL size with interleukin-6, an inflammatory cytokine and oxidized LDL, a marker of oxidative stress, in women with metabolic syndrome.
Chae JS; Kim OY; Paik JK; Kang R; Seo WJ; Jeong TS; Sweeney G; Lee SH; Lee JH
Atherosclerosis; 2011 Oct; 218(2):499-506. PubMed ID: 21762913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
